Skip to main
AKBA
AKBA logo

Akebia Therapeutics (AKBA) Stock Forecast & Price Target

Akebia Therapeutics (AKBA) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 42%
Buy 32%
Hold 26%
Sell 0%
Strong Sell 0%

Bulls say

Akebia Therapeutics Inc. is experiencing strong initial sales of its Vafseo product, with revenue projections expected to grow from $136 million in FY25 to $374 million by FY28, highlighting a significant market opportunity. The company's strategic focus on securing contracts with dialysis organizations has driven early commercial traction, with net sales guidance for the first quarter of 2025 anticipated to be between $10 million and $11 million, which is considerably higher than initial consensus estimates. Additionally, the company has demonstrated operational efficiency, recording combined R&D and SG&A expenses below consensus, prompting upward revisions in future spending estimates which support a positive outlook for continued growth.

Bears say

Akebia Therapeutics Inc. reported a net loss of $22.8 million in the fourth quarter of 2024, indicating ongoing financial difficulties as reflected in a loss of $0.10 per share. The company faces significant risks including a potentially limited commercial opportunity for Vafseo due to market dynamics and competition, alongside additional regulatory hurdles and intellectual property challenges that could delay product launches. Furthermore, projected revenues from their key products, Auryxia and Vafseo, indicate potential declines, particularly with Auryxia expected to experience reduced sales following its impending genericization, compounding the company’s financial uncertainties.

Akebia Therapeutics (AKBA) has been analyzed by 19 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 32% recommend Buy, 26% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Akebia Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Akebia Therapeutics (AKBA) Forecast

Analysts have given Akebia Therapeutics (AKBA) a Buy based on their latest research and market trends.

According to 19 analysts, Akebia Therapeutics (AKBA) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Akebia Therapeutics (AKBA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.